{
 "companyname": "RXI PHARMACEUTICALS CORP",
 "symbol": "RXII",
 "description": "Pharmaceutical Preparations",
 "quarters": [
  {
   "cik": "0001533040",
   "companyname": "RXI PHARMACEUTICALS CORP",
   "entityid": 866542,
   "primaryexchange": "Nasdaq Capital Market",
   "primarysymbol": "RXII",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0001193125-15-375630",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 286000,
   "changeincurrentliabilities": -157000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": 0,
   "cashfromfinancingactivities": 12000,
   "cashfrominvestingactivities": 0,
   "cashfromoperatingactivities": -1963000,
   "cfdepreciationamortization": 19000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 0,
   "netchangeincash": -1951000,
   "totaladjustments": 533000,
   "ebit": -2504000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -2496000,
   "interestexpense": null,
   "netincome": -2496000,
   "netincomeapplicabletocommon": -2496000,
   "researchdevelopmentexpense": 1734000,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 770000,
   "commonstock": 6000,
   "deferredcharges": null,
   "cashandcashequivalents": 4035000,
   "cashcashequivalentsandshortterminvestments": 12085000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 18000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 162000,
   "retainedearnings": -54489000,
   "totalassets": 12697000,
   "totalcurrentassets": 12517000,
   "totalcurrentliabilities": 1665000,
   "totalliabilities": 1665000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 11032000,
   "treasurystock": null
  },
  {
   "cik": "0001533040",
   "companyname": "RXI PHARMACEUTICALS CORP",
   "entityid": 866542,
   "primaryexchange": "Nasdaq Capital Market",
   "primarysymbol": "RXII",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "8/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0001193125-15-287233",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -367000,
   "changeincurrentliabilities": 266000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -31000,
   "cashfromfinancingactivities": 9237000,
   "cashfrominvestingactivities": -8031000,
   "cashfromoperatingactivities": -1800000,
   "cfdepreciationamortization": 20000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": -594000,
   "totaladjustments": 366000,
   "ebit": -2165000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -2166000,
   "interestexpense": null,
   "netincome": -2166000,
   "netincomeapplicabletocommon": -2190000,
   "researchdevelopmentexpense": 1361000,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 804000,
   "commonstock": 6000,
   "deferredcharges": null,
   "cashandcashequivalents": 5986000,
   "cashcashequivalentsandshortterminvestments": 14036000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 18000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 181000,
   "retainedearnings": -51993000,
   "totalassets": 14953000,
   "totalcurrentassets": 14754000,
   "totalcurrentliabilities": 1822000,
   "totalliabilities": 1822000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 13131000,
   "treasurystock": null
  },
  {
   "cik": "0001533040",
   "companyname": "RXI PHARMACEUTICALS CORP",
   "entityid": 866542,
   "primaryexchange": "Nasdaq Capital Market",
   "primarysymbol": "RXII",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/13/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0001193125-15-184836",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 91000,
   "changeincurrentliabilities": 222000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -8000,
   "cashfromfinancingactivities": 64000,
   "cashfrominvestingactivities": -8000,
   "cashfromoperatingactivities": -1972000,
   "cfdepreciationamortization": 21000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": -1916000,
   "totaladjustments": 973000,
   "ebit": -2946000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 34000,
   "incomebeforetaxes": -2945000,
   "interestexpense": null,
   "netincome": -2945000,
   "netincomeapplicabletocommon": -3130000,
   "researchdevelopmentexpense": 2107000,
   "totalrevenue": 34000,
   "sellinggeneraladministrativeexpenses": 873000,
   "commonstock": 3000,
   "deferredcharges": null,
   "cashandcashequivalents": 6580000,
   "cashcashequivalentsandshortterminvestments": 6630000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 18000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 21000,
   "propertyplantequipmentnet": 170000,
   "retainedearnings": -49827000,
   "totalassets": 7169000,
   "totalcurrentassets": 6981000,
   "totalcurrentliabilities": 1556000,
   "totalliabilities": 1556000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 2528000,
   "treasurystock": null
  }
 ]
}